News

The number of Americans with a history of cancer, currently estimated to be 13.7 million, will grow to almost 18 million by 2022, according to a first-ever report by the American Cancer Society in collaboration with the National...

Roche announced that the U.S. Food and Drug Administration has approved PerjetaTM.Perjeta is approved in combination with Herceptin® and docetaxel chemotherapy for the treatment of people with HER2-positive metastatic breast cancer (mBC) who have not received prior anti-HER2...

Conducting more clinical trials in developing countries is of benefit because these populations are underrepresented in research, but doing trials in resource poor settings has many challenges. Research sites in developing countries benefit from...

New long-term data for Gilenya® (fingolimod), the only oral therapy approved to treat people with relapsing forms of multiple sclerosis (MS), show a sustained efficacy benefit and a consistent safety profile with up to 4.5 years of continuous...

The Bristol-Myers Squibb Foundation has announced $6 million in additional grants through its Together on Diabetes™ initiative that will help more adults living with type 2 diabetes better manage their disease and make behavioral changes that can improve...

A study led by Karolinska Institutet reports for the first time the positive effects of an active vaccine against Alzheimer's disease. The new vaccine, CAD106, can prove a breakthrough in the search for a...

Abbott announced results from the Phase 3 ABILITY-2 investigational study of HUMIRA  in patients with active peripheral spondyloarthritis (PSpA) who have not been diagnosed with psoriatic arthritis (PsA) or ankylosing spondylitis (AS). At week 12, nearly...